We know that achieving success depends on selecting the right people, retaining the best staff and offering the best services and products. This is only possible due to the synergy between the experience and the scientific profile of the DermaLumics engineering team, the solid leadership profile and professionalism of the sales and marketing sector and the talent and dedication of all DermaLumics employees.
Eduardo Margallo obtained his M.Eng. degree in Telecommunications from the Polytechnic University of Madrid, an M.Sc. degree in Physics from UNED and an M.Eng. degree in Electrical Engineering (Dipl.-Ing. Elektrotechnik) from the University of Stuttgart (Germany). He completed his doctorate at Delft University of Technology (The Netherlands) in the field of biophotonic instrumentation. He has accumulated 8 years of experience in the design and manufacturing of biophotonic instrumentation and integrated optics, with an in-depth knowledge of the physics of light propagation in tissue, sensor microfabrication techniques and silicon photonic devices. Over this time he has participated in the definition and implementation of clinically driven research projects in collaboration with several universities and hospitals in the Netherlands and Italy. Eduardo co-founded MedLumics in 2009 and is currently its CEO and the President of DermaLumics, having guided the company through its seed and start-up phases. In particular, he led fund-raising activities resulting in a €3.5m A-round, which closed in November 2011.José Luis Rubio holds an M.Eng. degree in Telecommunications from the Polytechnic University of Madrid and he completed his doctorate at the same university, in the field of biomedical imaging. Over the past 8 years he has worked on the modelling and simulation of biomedical imaging systems, advanced reconstruction algorithms and on medical image processing. During the same period, he has participated in several projects in this area, at both national and European level, and has worked with universities, research centres and hospitals in Spain, France and the U.S. José Luis co-founded MedLumics in 2009 and is currently its CTO.
Josep Sanfeliu is co-founder of Ysios Capital Partners. His career is focused on the structuring of investment deals and, in particular, those concerned with medical technology. He is currently an observer on the Endosense board and a member of MedLumics’, DermaLumics' and SABIRMEDICAL’s boards". Josep’s specialities include financial evaluations, M & A and advising entrepreneurs with regard to IP matters. Josep has gained his experience in some of the most prestigious firms, starting out as an associate at Cuatrecasas in the fields of mergers and acquisitions, venture capital and intellectual property. He then went on to join the consulting firms KPMG or Eurohold Corporate Finance and focused on project innovation, business development and venture capital. Over the last 5 years Josep has been working, from a pharmaceutical and healthcare perspective, in the health sector, starting this stage of his career at Almirall as the Corporate Finance and Business Development Manager. There he worked on investment projects (mergers, acquisitions and venture capital) and business development projects (licensing, partnerships, joint ventures, etc.), both in Europe and the United States. His most recent position was that of Director General at SARDomus and steering committee member at the SAR group, where he was responsible for more than 300 professionals in the field of healthcare. Josep holds a degree in Law from the Universitat Pompeu Fabra in Barcelona, a Master’s degree in Law specialising in Intellectual Property and International Transactions from the University of Michigan, Ann Arbor, United States, and an MBA (Global Executive MBA) from IESE (Navarra University).Joël is Managing Partner and co-founder of Ysios Capital. He is currently a member of the board of directors of TiGenix, AM-Pharma, MedLumics, DermaLumics and Chairman of the board at Inbiomotion. He was formerly board observer at Biovex (now AMGEN) and Chairman of the board at Cellerix (now TiGenix). Previously, Joël co-founded GLYCART Biotechnology AG (Zürich, Switzerland) in March 2001 and was Chief Executive since inception. He raised €15 million in three rounds of financing for GLYCART before the company was sold to F. Hoffmann-La Roche Ltd in July 2005, a deal lauded as deal of the year by the European Venture Capital magazine. Joël holds a master’s degree in Biochemistry, specialising in Biotechnology, and a doctorate in the fields of cell biology and immunotherapeutics, both from the Swiss Federal Institute of Technology in Zürich. He was elected one of the 50 key players in biotechnology in Switzerland in 2003 and earned several innovation awards for GLYCART, including the Wall Street Journal Europe Innovation Award in 2001.José Antonio is the Chief Investment Officer at Caixa Capital Risc. He specialises in investment in biotechnology and medical devices. He currently serves on the board of directors at Omnia Molecular, Laboratoris Sanfit, MedLumics, DermaLumics and SABIRMEDICAL. He is responsible for the analysis, negotiation and structuring of processes in life science companies. José Antonio has more than 8 years of experience in the analysis of investment opportunities and specialises in the creation of and early health sector companies. His experience began in the Department of Business Development at Genzyme Corporation, a company specialising in the development and sale of drugs for orphan diseases. He later joined the Technology Portfolio team at Genoma España, a public sector foundation that promotes technology development, knowledge transfer and innovation, particularly in the biotechnology sector, where he specialised in the analysis of investment opportunities in start-up companies. José Antonio holds a degree in Biology and a Master’s in Corporate Finance from the University Complutense, Madrid (UCM) and a PDD IESE from the University of Navarra.Elena is Director of Operations at Caixa Capital Risc, the venture capital arm of "la Caixa" group (the leading financial group in Spain, in banking and insurance). She manages seven venture capital funds worth over 150 million euro, for investment in innovative start-ups with high growth potential.
Elena has over 10 years' experience in analysing start-up investment opportunities both at Caixa Capital, and previously, as head of business creation at the TechNova Innovation Park.
Elena holds a degree in telecommunications from La Salle University and an MBA.
Dr Reim studied Mathematics and Physics at ETH Zürich, Switzerland, obtaining his PhD in experimental physics at the same institution. He brings valuable experience to MedLumics as a result of the broad range of executive positions he has held at leading companies in the medical technology industry. He was CEO at Dräger Medical AG & Co. KG and a member of the Board of Directors at Drägerwerk AG for 7 years.
He was previously President of the Ultrasound Division at Siemens Healthcare, based in the US, and he has held top executive positions in areas such as magnetic resonance imaging, mammography, urology, lithotripsy, surgery, portable X-rays and accessories. At the beginning of his career, Dr Reim worked in the R&D centres of IBM and Siemens.
Wolfgang Reim currently sits on the board of directors at Carl Zeiss Meditec AG, GN Store Nord A/S, Ondal Medical Systems, Elekta AB, MedLumics S.L. and DermaLumics S.L.
View a list of our Board of Directors, along with a brief biography of each member and their experience.
Miguel Eslava started his professional career in the IT sector with Nixdorf Computer, later Siemens Nixdorf, in which he held a number of positions. He then joined Desarrollo Informático DINSA, company in which he developed the Services division. In 1997 Miguel Eslava joined General Electric, where for 12 years he held responsibilities at both national and international level. He was Country Manager of GE Healthcare Spain and Portugal, a group including GE Medical Systems S.A., GE Medical Systems Information Technology S.A., Datex Ohmeda S.L., Amersham Health S.A. and Amersham Health Radiofarmacos S.L. He was previously appointed General Sales Manager for GE Medical Systems Spain and Portugal, and he also held other positions within the GE group, including General Services Manager for GE Medical Systems, VP & COO for GE Capital ITS Spain and General Manager for GE Clinical Services for the whole EMEA region. Miguel is currently VP&COO of MedLumics and General Manager of DermaLumics, booth companies focused on the development, manufacturing and marketing of medical imaging equipment based on Optical Coherence Tomography (OCT). He holds advisory positions on the Boards of TBS, Proa Capital Private Equity and Grupo ACE. Nigel Wing graduated from the University of Hertfordshire with a degree in Manufacturing Systems Engineering in 1990. He has over 20 years managerial experience in all areas of manufacturing operations (Manufacturing, Quality, Supply Chain, Process Engineering, Maintenance, Excellence System) primarily in the automotive industry. Having completed a European MBA at IMEA in France, his career has taken an international orientation working in Switzerland, France, UK, Spain and Mexico in renown international groups including Nestlé, Faurecia, Valeo and Gonvarri.
A firm advocate of Continuous Improvement / LEAN cultures, Nigel is presently the Technical Manager of Dermalumics SL.